35 episodes
S&P Pharma Dose S&P Global Ratings
-
- Business
Hosted by Arthur Wong, Ji Liu, and other editors and analysts, the S&P Pharma Dose podcast from S&P Global Ratings discusses all things pharma from a credit perspective.
-
What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like
In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.
-
Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration
S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.
-
Episode 34: More Color on PPD’s Rating After IPO
In this episode of S&P Pharma Dose, senior healthcare analyst Ji Liu discusses his view on Pharmaceutical Product Development LLC (PPD) after its recent IPO on Feb. 5, 2020.
-
Episode 33: Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations
In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.
-
Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating
The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.
-
Episode 31: Thoughts On Pharma’s Washington Grilling
S&P Global’s pharmaceutical themed podcast show returns with some quick thoughts on the pharma industry’s testimony at a congressional hearing on Capitol Hill. A comprehensive list of challenges/criticisms of the industry, but where were the suggested solutions? Noise level on pharma pricing is only going to increase as we near presidential election.